VivoSeq
Other

NEC

0

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

NEC is an early-stage landscape with 0 programs across 5 companies. The most active players are Theracos, Boehringer Ingelheim, VistaGen Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

93/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Theracos logo

Theracos

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalV

VistaGen Therapeutics, Inc.

0 programs

PreclinicalSunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed13 · 65%
Unknown status4 · 20%
Recruiting2 · 10%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

20 trials

Study of Trilaciclib and Lurbinectidin
Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05578326·30 enrolled
Nectero EAST System Clinical Study
Recruiting·NNectero Medical, Inc.·Phase 2/3·NCT06001918·400 enrolled
Application of Tachosil During Lymphadenectomy
Completed·MMedical University of Lublin·Phase 4·NCT03752606·50 enrolled
Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
Completed·VVA Office of Research and Development·Phase 1·NCT02243631·8 enrolled
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
Completed·Theracos logoTheracos·Phase 1·NCT03296800·48 enrolled
A Study in Healthy People to Test How 2 Different Formulations of BI 690517 Are Taken up in the Body and How Probenecid Influences the Amount of BI 690517 in the Blood
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT06647810·15 enrolled
Connecting Resources for Urban Sexual Health
Completed·UUniversity of California, San Francisco·N/A·NCT02183909·378 enrolled
Gynecological Sentinel Lymph Nodes CEUS
Completed·TThomas Jefferson University·Phase 1·NCT05105087·9 enrolled
Fibrin Glue in Inguinal Lymphadenectomy
Completed·MMenoufia University·N/A·NCT04666051·32 enrolled
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
Completed·Sunshine Lake Pharma Co., Ltd. logoSunshine Lake Pharma Co., Ltd.·Phase 1·NCT05497674·28 enrolled
Comparative Safety Study of New Sinecort Formulation Versus Positive Control
Completed·Bayer logoBayer·Phase 1·NCT00885937·33 enrolled
Prophylactic Anecortave Acetate in Patients With a Retisert Implant
Completed·TTexas Retina Associates·Phase 1·NCT00570479·12 enrolled
Study of Mitomycin C and Nasal Splint to Treat Nasal Synechiae
Completed·—·Phase 2·NCT00966056·60 enrolled
Addition of Probenecid to Penicillin-V Therapy
Completed·IImperial College London·Phase 1/2·NCT05082909·21 enrolled
Avelumab in G3 NEC
Completed·SSunnybrook Health Sciences Centre·Phase 1/2·NCT03278405·10 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)